Maria Jesús Vidal
Grup de recerca
- Genòmica translacional i teràpies dirigides en tumors sòlids Accredited researcher (R3A)
Publicacions destacades
-
Sentinel node after NeoAdjuvancy in node-positive breast cancer. SANA multicentric study
Autors:Referència: European Journal Of Cancer 2020. -
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial
Autors:Referència: Jama Oncology 2020. -
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Autors:Referència: Breast Cancer Research 2020. -
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Autors:Referència: Cancer Treatment Reviews 2020. -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Autors:Referència: Nature Communications 2020. -
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Autors:Referència: Journal Of The National Cancer Institute 2020. -
PAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer
Autors:Referència: Annals Of Oncology 2019.
Projectes destacats
-
HER2-enriched molecular subtype as a predictor of response to dual HER2 blockade.
Investigador/a principal: Aleix PratFinançador: Beca Susan Komen (Sede o evento)Durada: 01/01/2014 - 01/01/2016 -
Predictores de Respuesta a la Quimioterapia en Cáncer de Mama Triple-Negativo con un Perfil Molecular Basal-like.
Investigador/a principal: Aleix PratFinançador: Beca Sandra Ibarra (Sede o evento)Durada: 01/01/2013 - 01/01/2013 -
Molecular Quantification of Estrogen Receptor Partners for Endocrine Response Prediction.
Finançador: Universidad de Oslo (Sede o evento)Durada: 01/01/2012 - 01/01/2016